{"id":61242,"date":"2026-03-25T14:30:40","date_gmt":"2026-03-25T06:30:40","guid":{"rendered":"https:\/\/flcube.com\/?p=61242"},"modified":"2026-03-25T14:30:41","modified_gmt":"2026-03-25T06:30:41","slug":"asieris-pharma-partners-with-sph-keyuan-to-commercialize-cevira-worlds-first-non-surgical-cervical-precancer-treatment-launches-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61242","title":{"rendered":"Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira \u2013 World’s First Non\u2011Surgical Cervical Precancer Treatment Launches in China"},"content":{"rendered":"\n

Jiangsu Asieris Pharmaceuticals Co., Ltd.<\/strong> (SHA: 688176<\/a>), a urogenital cancer specialist<\/strong>, has entered into a strategic partnership<\/strong> with SPH Keyuan Trade<\/strong> to accelerate commercialization of Cevira<\/strong>, a photodynamic drug\u2011device combination product<\/strong> approved earlier this month for cervical high\u2011grade squamous intraepithelial lesions (HSIL\/CIN2)<\/strong> \u2013 marking the world’s first non\u2011surgical, non\u2011invasive treatment<\/strong> for cervical precancerous lesions.<\/p>\n\n\n\n

Partnership Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Companies<\/strong><\/td>Jiangsu Asieris Pharmaceuticals (SHA: 688176) + SPH Keyuan Trade<\/td><\/tr>
Product<\/strong><\/td>Cevira \u2013 photodynamic drug\u2011device combination<\/td><\/tr>
Partnership Focus<\/strong><\/td>China commercialization acceleration<\/td><\/tr>
Strategic Rationale<\/strong><\/td>Leverage respective advantages (Asieris: R&D\/product; SPH Keyuan: distribution\/commercial)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile \u2013 Cevira Innovation<\/h2>\n\n\n\n
Feature<\/th>Specification<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Photodynamic therapy (PDT)<\/strong> \u2013 drug\u2011device combination<\/td>Light\u2011activated tumor cell destruction<\/td><\/tr>
Indication<\/strong><\/td>Cervical HSIL (CIN2)<\/strong> \u2013 histologically confirmed<\/td>High\u2011grade precancerous lesions<\/td><\/tr>
Patient Population<\/strong><\/td>Adults \u226518 years<\/td>Reproductive\u2011age women<\/td><\/tr>
Global First<\/strong><\/td>World’s first non\u2011surgical, non\u2011invasive<\/strong> cervical precancer treatment<\/td>Eliminates surgical morbidity; preserves fertility<\/td><\/tr>
Paradigm Shift<\/strong><\/td>Replaces destructive invasive\/minimally invasive procedures<\/strong> (LEEP, cone biopsy, laser)<\/td>Outpatient administration; no tissue destruction; cervical preservation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Unmet Need<\/h2>\n\n\n\n
Dimension<\/th>Traditional Cervical HSIL Treatment<\/th>Cevira Value Proposition<\/th><\/tr><\/thead>
Standard of Care<\/strong><\/td>LEEP (loop electrosurgical excision), cold knife cone biopsy, laser ablation<\/td>Non\u2011invasive photodynamic therapy<\/strong> \u2013 no surgical risk<\/td><\/tr>
Procedure Risks<\/strong><\/td>Bleeding, infection, cervical stenosis, preterm birth risk in future pregnancies<\/td>Fertility\u2011preserving<\/strong> \u2013 critical for reproductive\u2011age women<\/td><\/tr>
Patient Experience<\/strong><\/td>Operating room procedure; anesthesia; recovery time<\/td>Outpatient\/office\u2011based<\/strong>; minimal downtime<\/td><\/tr>
Treatment Gap<\/strong><\/td>No approved non\u2011invasive pharmacological options<\/td>First\u2011and\u2011only<\/strong> non\u2011surgical alternative<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Strategic Outlook<\/h2>\n\n\n\n